Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(159 products)
- Bcr-Abl(115 products)
- EGFR(594 products)
- FAK(72 products)
- FLT(90 products)
- Fibroblast Growth Factor Receptor (FGFR)(182 products)
- JAK(246 products)
- PDGFR(126 products)
- RAAS(90 products)
- Src(81 products)
- Syk(37 products)
- Thrombin(53 products)
- VDA(2 products)
- VEGFR(249 products)
Show 6 more subcategories
Found 2092 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
FGFR-IN-5
CAS:FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.Formula:C25H22N6O3Color and Shape:SolidMolecular weight:454.48MTX-216
CAS:MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Formula:C22H14Cl2FN5O2SColor and Shape:SolidMolecular weight:502.348Oxamic acid
CAS:Oxamic acid is an LDHA inhibitor, antitumor, induces apoptosis, downregulates EGFR expression, and inhibits cancer stem cell properties and EMT.Formula:C2H3NO3Color and Shape:SolidMolecular weight:89.05EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96VEGFR-2-IN-12
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.Formula:C22H24N6O3SColor and Shape:SolidMolecular weight:452.53EGFR-IN-45
EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.Formula:C28H23N7OColor and Shape:SolidMolecular weight:473.53BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formula:C29H33ClN8O4Color and Shape:SolidMolecular weight:593.08FLT3/TrKA-IN-1
FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.Formula:C28H30N4O2Color and Shape:SolidMolecular weight:454.56Cernuumolide J
CAS:Cernuumolide J (TMJ-105) functions as a JAK2/STAT3 inhibitor and exhibits potent activity against HEL leukemia cells by inhibiting their growth in both time-dependent and concentration-dependent manners, with an IC 50 value of 1.79 μM. This compound effectively induces G2/M phase arrest and apoptosis by downregulating the phosphorylation of JAK2, STAT3, and Erk, while simultaneously upregulating the phosphorylation of JNK and p38 MAPK. Cernuumolide J holds potential for research applications in anti-cancer therapy.Formula:C24H34O8Color and Shape:SolidMolecular weight:450.52DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColor and Shape:SolidMolecular weight:400.362NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Formula:C19H15F3N2O2Color and Shape:SolidMolecular weight:360.33VEGFR-2-IN-25
CAS:VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).Formula:C24H22N6O2Color and Shape:SolidMolecular weight:426.47VEGFR-2-IN-26
CAS:VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.Formula:C24H19F3N6O2Color and Shape:SolidMolecular weight:480.44EGFR-IN-146
CAS:EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Formula:C20H16N4Color and Shape:SolidMolecular weight:312.368Tyk2-IN-10
CAS:Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Formula:C25H27N5O3Color and Shape:SolidMolecular weight:445.51FAK-IN-6
FAK-IN-6: Potent FAK inhibitor (IC50=1.415 nM), anti-cancer, for pancreatic studies.Formula:C25H31ClN5O6PSColor and Shape:SolidMolecular weight:596.04VEGFR-2-IN-52
CAS:VEGFR-2-IN-52 (compound 14d) serves as a powerful inhibitor of VEGFR-2, exhibiting an IC 50 of 191.1 nM. It effectively reduces the protein expression levels of p-VEGFR-2, MMP9, p-ERK1/2, and p-MEK1. In addition, VEGFR-2-IN-52 demonstrates cytotoxic properties by inducing apoptosis and arresting the cell cycle at the G0/G1 phase, and it enhances the levels of ROS.Formula:C20H25ClN4O2SColor and Shape:SolidMolecular weight:420.96Lomonitinib
CAS:<p>Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.</p>Formula:C27H24N4O2Color and Shape:SolidMolecular weight:436.505LT-850-166
LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.Formula:C30H29Cl2N7OColor and Shape:SolidMolecular weight:574.5MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formula:C28H44N8O5Purity:98%Color and Shape:SolidMolecular weight:572.70Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Color and Shape:SolidMolecular weight:599.08Lucitanib dihydrochloride
CAS:Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.Formula:C26H27Cl2N3O4Color and Shape:SolidMolecular weight:516.42FGFR-IN-6
CAS:FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Formula:C23H22N6O3Color and Shape:SolidMolecular weight:430.46EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58GLPG3312
CAS:GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .Formula:C23H21F2N5O3Purity:98.53%Color and Shape:SolidMolecular weight:453.44FGFR4-IN-10
FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.Formula:C20H19F3N6O3Color and Shape:SolidMolecular weight:448.4FAK-IN-2
FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.Formula:C28H31ClN8O3Color and Shape:SolidMolecular weight:563.05EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Color and Shape:SolidVEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Formula:C20H21N3O2Color and Shape:SolidMolecular weight:335.4ALK-IN-31
CAS:ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).Formula:C30H33N5O2SColor and Shape:SolidMolecular weight:527.68EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64CDD-1115
CAS:<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Formula:C32H30N6O3Color and Shape:SolidMolecular weight:546.619BTK-IN-7
BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.Formula:C30H32N6O4Color and Shape:SolidMolecular weight:540.61EGFR/HER2-IN-6
EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.Formula:C18H21N5O3SColor and Shape:SolidMolecular weight:387.46FGFR4-IN-6
FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.Formula:C31H33N7O4Color and Shape:SolidMolecular weight:567.64FGFR4-IN-9
FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.Formula:C24H22ClF3N4O4Color and Shape:SolidMolecular weight:522.9EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formula:C27H31ClN7O3PColor and Shape:SolidMolecular weight:568.01AFP464 free base
CAS:AFP464 (NSC710464) free base is an active HIF-1α inhibitor (IC50: 0.25 μM) and a potent aryl hydrocarbon receptor (AhR) activator.Formula:C22H23F3N4O3Purity:98%Color and Shape:SolidMolecular weight:448.44E7090 succinate
CAS:E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.Formula:C76H92N10O24Color and Shape:SolidMolecular weight:1529.60Antiallergic agent-1
Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.Formula:C27H19F6N5OColor and Shape:SolidMolecular weight:543.46TTT 3002
CAS:TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.Formula:C27H23N5O3Color and Shape:SolidMolecular weight:465.50JAK2 JH2 binder-1
CAS:JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96SJ1008066
CAS:SJ1008066 is a MAGE-A11 inhibitor with an IC50 of 0.13 μM. It binds to the MAGE homology domain (MHD) and disrupts the MAGE-A11:PCF11 interaction.Formula:C21H22N4Color and Shape:SolidMolecular weight:330.43T-1-PMPA
CAS:T-1-PMPA, a potent EGFR inhibitor, demonstrates apoptotic properties and effectively inhibits EGFR WT and EGFR 790m, with IC50 values of 86 nM and 561.73 nM, respectively [1].Formula:C16H17N5O3Molecular weight:327.34TAS05567
CAS:TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Formula:C21H29N9O2Purity:98%Color and Shape:SolidMolecular weight:439.51FAK-IN-3
<p>FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.</p>Formula:C28H28N6O4Color and Shape:SolidMolecular weight:512.56
